|
|
|
|
|
|
|
|
|
|
Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer
Conclusion
In conjunction with the
demonstrated safety, the high rate of induction of T-cell activation and
correlation with improvement in RFS justify further Phase II/III
assessment of Vigil.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.